Tozorakimab for Acute Respiratory Failure

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Acute Respiratory FailureTozorakimab - Drug
Eligibility
18 - 18
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.

Eligible Conditions
  • Acute Respiratory Failure

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

0 Primary · 15 Secondary · Reporting Duration: by Day 60

Day 1
Baseline serum interleukin-33/soluble Suppression of Tumorgenicity 2 (IL-33/sST2) complex levels relative to primary endpoint
by Day 28
Proportion of participants who die
Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)
by Day 60
Proportion of participants alive and discharged
Proportion of participants with Intensive Care Unit (ICU) admission or death
World Health Organization (WHO) 10-category ordinal Clinical Progression Scale
over 60 day period
Incidence of anti-drug antibodies
Number of days alive and free of Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)
Number of days alive and free of supplemental oxygen
Number of days alive and outside of Intensive Care Unit (ICU)
Number of days alive and ventilator free
Time to being off supplemental oxygen
Time to death (all cause)
Time to death or progression to IMV/ECMO
Time to discharge

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Tozorakimab
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

2352 Total Participants · 2 Treatment Groups

Primary Treatment: Tozorakimab · Has Placebo Group · Phase 3

Tozorakimab
Drug
Experimental Group · 1 Intervention: Tozorakimab · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: by day 60

Who is running the clinical trial?

AstraZenecaLead Sponsor
3,993 Previous Clinical Trials
247,416,228 Total Patients Enrolled

Eligibility Criteria

Age 18 - 18 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: